The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Biologically active GLP-1 7–36 amide is derived from proglucagon through post-translational processing. Proglucagon is generated throughout the small and large intestines in specialized ...

Creating a novel drug has always been a risky endeavor for biopharmaceutical companies. Developers and investors face ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

A drug normally used to treat diabetes can significantly reduce your risk of developing dementia, new research has revealed.

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a ...

A common diabetes drug could prevent dementia, with a longer treatment being related with more benefits, a study on Korean population has suggested. In over two lakh adults aged 40-69 years and having ...

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety ...